Shares of Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) climbed 50 percent to $4.80 on Monday as – more than a year after FDA approval of Symjepi (epinephrine), its competitor for Mylan NV’s Epipen and other emergency epinephrine products – it secured a U.S. distributor and commercial partner for the product. Under terms of the 10-year deal, Adamis and Novartis Group’s generics arm, Sandoz Inc., will equally split net profits from sales of the single-dose pre-filled syringe of epinephrine.